Form D · Biotechnology
Editas Medicine, Inc.
Cambridge, MA · CIK 0001650664
Offering snapshot reported Aug 18, 2015 · SEC filing
- Reported sold
- $120M Offering amount: $120M
- Investors reported
- 43 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 4, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 18, 2015 | Initial | $119,999,970 | No comparison | 43 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-245968
Source: Form D, filed Aug 18, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kevin Bitterman | Director |
| Alexis Borisy | Director |
| Katrine Bosley | Director, Executive |
| Douglas Cole | Director |
| Alexandra Glucksmann | Executive |
| Andrew Hack | Executive |
| Vic Myer | Executive |
| Boris Nikolic | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
300 Third Street First Floor
Cambridge, MA, 02142
Cambridge, MA, 02142